药学研究2024，Vol.43Issue(4)：313-318,337,7.DOI:10.13506/j.cnki.jpr.2024.04.001
解毒化瘀退黄方对乙肝相关CNLC Ⅳ期湿热瘀阻证患者炎症介质的影响及临床疗效
Effect and clinical efficacy of Jiedu Huayu Tuihuang Prescription on inflammatory factors in patients with dampness-heat stasis syndrome at CNLC Ⅳ stage related HBV
摘要
Abstract
Objective To observe the clinical efficacy and safety of Jiedu Huayu Tuihuang Prescription in patients with dampness-heat stasis syndrome at CNLC Ⅳ stage related HBV.Methods From January 2021 to June 2022,72 patients with dampness-heat stasis syndrome at the CNLC Ⅳstage related HBV were diagnosed at the Hepatology Department of our hospital.The patients were randomly divided into a control group and a Prescription group,each consisting of 36 cases.The control group was treated with western medicine,and the Prescription group received western medicine and Jiedu Huayu Tu-ihuang Prescription orally.The courses of treatment in the two groups were 12 weeks,with a 24-week follow-up.Before treatment and at 4 and 12 weeks after treatment,we compared several aspects in the two groups.These aspects included tumor size,tumor number,TCM syndrome score,cytokine levels,tumor markers,biochemical indices,Child-Pugh grading score,physical and functional status score,and survival rate of patients.Results After 4 weeks of treatment,the tumor size of the Prescription group increased slowly compared to the control group.Furthermore,the clinical syndrome score,IL-1β,IL-6,AFP,AFP-L3,TBIL,PT and Child-Pugh grades of the Prescription group decreased,and ALB increased compared to the control group.The KPS also decreased and delayed in the Prescription group.After 12 weeks of treatment,in the Pre-scription group,the size and number of tumors increased slowly compared with the control group.The clinical syndrome score,TNF-α,IL-1β,IL-6,AFP,AFP-L3,DCP,ALT,AST,TBIL,PT and Child-Pugh grades in the Prescription group were lower than those in the control group,and ALB was higher than that in the control group.KPS in the Prescription group was lower than that in the control group.ZPS increased slowly compared with the control group.The clinical efficacy and sur-vival rate of the prescription group were higher than that of control group.Conclusion Jiedu Huayu Tuihuang Prescription can inhibit tumor growth on patients with dampness-heat stasis syndrome at CNLC Ⅳ stage related HBV.It also reduces TCM syndrome scores and levels of TNF-α,IL-1β,IL-6,AFP,AFP-L3,DCP,ALT,AST,TBIL,PT and Child-Pugh grad-ing,Liver function also improved.This treatment delays the deterioration of physical strength and functional status,signifi-cantly improving the clinical efficacy and life quality with tumor of patients with dampness-heat stasis syndrome at CNLCⅣstage related HBV.关键词
解毒化瘀退黄方/中国肝癌分期Ⅳ期/炎症介质/临床疗效Key words
Jiedu Huayu Tuihuang Prescription/CNLC IV stage/Inflammatory factor/Clinical effect分类
中医学引用本文复制引用
杨钒,石清兰,柏文婕,毛德文,封佩佩,杨敏,陶向君,黄乾铭,潘佩佩..解毒化瘀退黄方对乙肝相关CNLC Ⅳ期湿热瘀阻证患者炎症介质的影响及临床疗效[J].药学研究,2024,43(4):313-318,337,7.基金项目
国家自然科学基金资助项目(No.82060847) （No.82060847）
广西自然科学基金资助项目(No.2023GXNSFDA026033) （No.2023GXNSFDA026033）
广西中医药大学研究生教育创新计划项目(No.YCSZ2022025) （No.YCSZ2022025）
